Cubist Systematic Strategies LLC Invests $170,000 in Seres Therapeutics Inc (MCRB)

Cubist Systematic Strategies LLC acquired a new stake in Seres Therapeutics Inc (NASDAQ:MCRB) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 10,572 shares of the biotechnology company’s stock, valued at approximately $170,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in MCRB. Voya Investment Management LLC acquired a new stake in shares of Seres Therapeutics in the second quarter valued at about $114,000. Advisor Group Inc. lifted its stake in shares of Seres Therapeutics by 100.7% in the second quarter. Advisor Group Inc. now owns 14,050 shares of the biotechnology company’s stock valued at $160,000 after purchasing an additional 7,050 shares during the period. State of Wisconsin Investment Board acquired a new stake in shares of Seres Therapeutics in the second quarter valued at about $169,000. Aperio Group LLC acquired a new stake in shares of Seres Therapeutics in the third quarter valued at about $191,000. Finally, The Manufacturers Life Insurance Company lifted its stake in shares of Seres Therapeutics by 15.2% in the second quarter. The Manufacturers Life Insurance Company now owns 18,270 shares of the biotechnology company’s stock valued at $206,000 after purchasing an additional 2,410 shares during the period. Hedge funds and other institutional investors own 75.94% of the company’s stock.

Seres Therapeutics Inc (NASDAQ MCRB) opened at $10.52 on Friday. The company has a current ratio of 6.53, a quick ratio of 6.53 and a debt-to-equity ratio of 0.11. The stock has a market cap of $430.83, a PE ratio of -4.96 and a beta of 0.22. Seres Therapeutics Inc has a 52-week low of $8.85 and a 52-week high of $17.42.

Seres Therapeutics (NASDAQ:MCRB) last posted its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.22. The business had revenue of $23.00 million during the quarter, compared to analyst estimates of $17.29 million. Seres Therapeutics had a negative net margin of 267.15% and a negative return on equity of 82.11%. The company’s revenue was up 76.9% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.46) earnings per share. equities analysts expect that Seres Therapeutics Inc will post -2.33 EPS for the current year.

Several analysts recently commented on the stock. Zacks Investment Research cut shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, October 11th. ValuEngine cut shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, September 21st. Citigroup assumed coverage on shares of Seres Therapeutics in a research report on Thursday, October 12th. They set a “positive” rating and a $19.00 target price for the company. Cowen restated a “buy” rating on shares of Seres Therapeutics in a research report on Monday, October 2nd. Finally, Oppenheimer assumed coverage on shares of Seres Therapeutics in a research report on Thursday, October 12th. They set an “outperform” rating and a $19.00 target price for the company. Two analysts have rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $18.00.

ILLEGAL ACTIVITY NOTICE: “Cubist Systematic Strategies LLC Invests $170,000 in Seres Therapeutics Inc (MCRB)” was originally posted by Stock Observer and is owned by of Stock Observer. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark law. The legal version of this piece of content can be accessed at https://www.thestockobserver.com/2018/01/13/cubist-systematic-strategies-llc-invests-170000-in-seres-therapeutics-inc-mcrb.html.

About Seres Therapeutics

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Want to see what other hedge funds are holding MCRB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Seres Therapeutics Inc (NASDAQ:MCRB).

Institutional Ownership by Quarter for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply